I'm not about to sign up for a subscription, so I can't be sure, but I think I remember about a year or so ago the Wall Street Journal's editorial page dismissing the concerns over Vioxx as "non-existent." I could be wrong though. It could be that non-existent referred instead to Merck's academic integrity.
The editors at one of the world's leading medical journals have accused researchers and Vioxx manufacturer Merck & Co. of withholding key heart risk data that showed up in one of the first large trials of the now-withdrawn arthritis painkiller.Seriously, when the day is done, what's a few heart attacks among friends?
Specifically, the editors of the New England Journal of Medicine charged that a major study published in November 2000 was submitted to the journal after information about three heart attacks among Vioxx trial participants was deleted by Merck, which funded the study.